Imipenem/Cilastatina Hikma

Imipenem, the active ingredient in Imipenem/Cilastatin Hikma, is a carbapenem antibiotic presented as an injectable solution for intravenous use. It treats a range of serious bacterial infections, including intra‑abdominal, urinary, pulmonary, skin and soft‑tissue infections, as well as severe sepsis, in hospitalized adult patients.

GNH USA supplies Imipenem/Cilastatin Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance, and reliable delivery across global markets.

Imipenem/Cilastatin is a carbapenem antibiotic indicated for severe bacterial infections affecting various organ systems.

- Complicated intra‑abdominal infections: provides rapid bacterial eradication to resolve intra‑abdominal sepsis. - Complicated urinary tract infections: offers broad‑spectrum activity to treat resistant uropathogens. - Nosocomial pneumonia (including ventilator‑associated pneumonia): delivers effective coverage against Gram‑negative and Gram‑positive pathogens in hospital‑acquired lung infections. - Skin and soft‑tissue infections: offers potent activity for serious cellulitis and wound infections. - Severe sepsis and septic shock: supplies critical antimicrobial support to improve outcomes in systemic infection.

The safety profile of Imipenem/Cilastatin includes both frequent and infrequent adverse reactions that clinicians monitor during therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Rash: skin erythema or pruritus. - Elevated liver enzymes: transient increase in transaminases. - Injection site pain: discomfort at the IV site.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or high doses. - Anaphylaxis: severe allergic reaction requiring immediate intervention. - Clostridioides difficile colitis: antibiotic‑associated intestinal infection. - Neutropenia: marked reduction in white blood cell count. - Renal dysfunction: worsening kidney function in susceptible individuals.

Prior to initiating Imipenem/Cilastatin therapy, healthcare providers should consider several precautionary measures to minimize risk.

- Renal function assessment: adjust dose in patients with impaired clearance. - Seizure risk evaluation: avoid high doses in individuals with a history of seizures or CNS disorders. - Allergy screening: confirm no known hypersensitivity to β‑lactam antibiotics or cilastatin. - Concomitant nephrotoxic drugs: monitor closely when used with aminoglycosides or vancomycin. - Electrolyte monitoring: watch for hypokalemia during prolonged therapy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Imipenem/Cilastatin may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Valproic acid: concomitant use can reduce valproate levels, risking seizure breakthrough. - Carbapenem‑inducing agents: may increase risk of seizures when combined with high‑dose carbapenems.

Moderate Interactions (Monitor Closely): - Aminoglycosides: additive nephrotoxicity; monitor renal function. - Vancomycin: potential for increased nephrotoxic effect; assess kidney markers. - Diuretics: may exacerbate electrolyte disturbances; check serum potassium. - Oral contraceptives: possible reduction in hormonal efficacy; advise alternative contraception.